Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR4 | Q13639 | 17/20 | 0.41 |
| ▸ | ACHE | P22303 | 8/20 | 0.37 |
| ▸ | MEN1 | O00255 | 1/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.35 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.35 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.35 |
| ▸ | TSHR | P16473 | 1/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14965437 | 0.93 | HTR4 (0.41) | HTR4ACHE | |
| SCHEMBL14968762 | 0.86 | EPHX2 (0.38) | HTR4MEN1ALDH1A1KMT2A | |
| SCHEMBL14968763 | 0.86 | EPHX2 (0.38) | HTR4MEN1ALDH1A1KMT2A | |
| SCHEMBL14965473 | 0.80 | EPHX2 (0.43) | HTR4ALDH1A1 | |
| SCHEMBL14968860 | 0.78 | CHEK1 (0.57) | — | |
| SCHEMBL2589855 | 0.75 | HTR4 (0.36) | HTR4 | |
| SCHEMBL14965412 | 0.75 | CHEK1 (0.41) | HTR4MEN1KMT2A | |
| SCHEMBL2589853 | 0.74 | SMN1; SMN2 (0.43) | MEN1ALDH1A1KMT2A | |
| SCHEMBL29287711 | 0.73 | BCHE (0.39) | — | |
| SCHEMBL14965514 | 0.72 | HTR4 (0.37) | HTR4ACHEALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170247341-A1 | PHARMACEUTICALLY ACTIVE PYRAZINE DERIVATIVES | SENTINEL ONCOLOGY LIMITED (GB) | 2017-08-31 | — | — | US | disclosed |
| US-9630931-B2 | Pharmaceutically active pyrazine derivatives | SENTINEL ONCOLOGY LIMITED (GB) | 2017-04-25 | — | — | US | disclosed |
| EP-2780331-B1 | PHARMACEUTICALLY ACTIVE PYRAZINE DERIVATIVES | SENTINEL ONCOLOGY LTD (GB) | 2016-04-20 | — | — | EP | disclosed |
| US-20140323484-A1 | Pharmaceutically Active Pyrazine Derivatives | SENTINEL ONCOLOGY LIMITED (GB) | 2014-10-30 | — | — | US | disclosed |
| EP-2780331-A1 | PHARMACEUTICALLY ACTIVE PYRAZINE DERIVATIVES | Sentinel Oncology Limited (GB) | 2014-09-24 | — | — | EP | disclosed |
| WO-2013072502-A1 | PHARMACEUTICALLY ACTIVE PYRAZINE DERIVATIVES | SENTINEL ONCOLOGY LIMITED (GB) | 2013-05-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140323484-A1 | Pharmaceutically Active Pyrazine Derivatives | PHKG1, PHKG2, PLK2 | HTR4 933/4885ACHE 3972/4885MEN1 2168/4885 |
| US-20170247341-A1 | PHARMACEUTICALLY ACTIVE PYRAZINE DERIVATIVES | PHKG1, PHKG2, PEAK1 | HTR4 775/4885ACHE 4049/4885MEN1 1807/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.